Swiss Pharma Company – IDEOGEN takes over Special Access Program for BELEODAQ® (belinostat)

IDEOGEN GROUP, Managed Access division, takes over Special Access Program for BELEODAQ® (belinostat) in Europe, Middle East, North Africa, Russia, and CIS. BELEODAQ® is a prescription medicine used to treat patients with a rare form of blood cancer called peripheral T-cell lymphoma (PTCL) that relapsed or does not respond to previous treatment. PTCL is a group of rare […]

thaipr.net

24 ม.ค. 65

Applied Pharmaceutical Science Inc. Announces FDA Approval of Investigational New Drug Application for APS03118, a Next generation RET Original New Drug for Unlimited Cancers

Applied Pharmaceutical Science, Inc. (“APS” or “the Company”), has recently announced the Investigational New Drug (IND) application for its self-developed breakthrough new drug APS03118, a next generation selective RET inhibitor, has been approved by the U.S. Food and Drug Administration (FDA). The clinical application is also in the process of being submitted to the National […]

thaipr.net

24 ม.ค. 65
1 2,496 2,497 2,498 2,499 2,500 3,319